<code id='8AAA336445'></code><style id='8AAA336445'></style>
    • <acronym id='8AAA336445'></acronym>
      <center id='8AAA336445'><center id='8AAA336445'><tfoot id='8AAA336445'></tfoot></center><abbr id='8AAA336445'><dir id='8AAA336445'><tfoot id='8AAA336445'></tfoot><noframes id='8AAA336445'>

    • <optgroup id='8AAA336445'><strike id='8AAA336445'><sup id='8AAA336445'></sup></strike><code id='8AAA336445'></code></optgroup>
        1. <b id='8AAA336445'><label id='8AAA336445'><select id='8AAA336445'><dt id='8AAA336445'><span id='8AAA336445'></span></dt></select></label></b><u id='8AAA336445'></u>
          <i id='8AAA336445'><strike id='8AAA336445'><tt id='8AAA336445'><pre id='8AAA336445'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:fashion    Page View:3698

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In